Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Choroidal Neovascularization Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Choroidal Neovascularization Therapeutics market. The report identifies the key trends shaping and driving the global Choroidal Neovascularization Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Choroidal Neovascularization Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Choroidal Neovascularization Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Choroidal Neovascularization Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Choroidal Neovascularization Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Choroidal Neovascularization Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Choroidal Neovascularization Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Choroidal Neovascularization Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Choroidal Neovascularization Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Choroidal Neovascularization Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

F. Hoffmann-La Roche
Bayer AG
Regeneron Pharmaceuticals, Inc.

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Choroidal Neovascularization Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 8
2.4 Signs and Symptoms 8
2.5 Diagnosis 8
2.5.1 History 8
2.5.2 Amsler Grid 9
2.5.3 Fluorescein angiography 9
2.5.4 Optical Coherence Tomography (OCT) 9
2.5.5 Opthalmoscopy or Fundoscopy 9
2.5.6 Visual acuity testing 9
2.6 Treatment and Management Pattern 10
2.7 GlobalData Pipeline Report Guidance 11
3 Choroidal NeovascularizationTherapeutics - Market Characterization 12
3.1 Overview 12
3.2 Choroidal Neovascularization Therapeutics Market Size 12
3.3 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Global 12
3.4 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Global 14
3.5 Choroidal Neovascularization Therapeutics Market Size (2005-2010) –  The US 15
3.6 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – The US 16
3.7 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – France 17
3.8 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – France 18
3.9 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Germany 19
3.10 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Germany 20
3.11 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Italy 21
3.12 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Italy 22
3.13 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Spain 23
3.14 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Spain 24
3.15 Choroidal Neovascularization Therapeutics Market Size (2005-2010) –  The UK 25
3.16 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – The UK 26
3.17 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Japan 27
3.18 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Japan 28
3.19 Drivers and Barriers for the Choroidal Neovascularization Therapeutics Market 29
3.19.1 Drivers for the Choroidal Neovascularization Therapeutics Market 29
3.19.2 Barriers for the Choroidal Neovascularization Therapeutics Market 29
3.20 Opportunity and Unmet Need Analysis 29
3.21 Key Takeaway 30
4 Choroidal Neovascularization Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile for the Major Marketed Products in the CNV Therapeutics market 32
4.3.1 Lucentis (ranibizumab) 32
4.3.2 Visudyne (verteporfin) 34
4.3.3 Macugen (pegatanib sodium) 35
4.3.4 Avastin (bevacizumab) 36
4.4 Key Takeaway 37
5 Choroidal Neovascularization Therapeutics - Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Choroidal Neovascularization Therapeutics Pipeline – Pipeline by Phases of Development 38
5.3.1 Choroidal Neovascularization Therapeutics – Phase III Pipeline 39
5.3.2 Choroidal Neovascularization Therapeutics – Phase II Pipeline 39
5.3.3 Choroidal Neovascularization Therapeutics – Phase I Pipeline 40
5.3.4 Choroidal Neovascularization Market – Discovery and Pre-clinical Pipeline 40
5.4 Technology Trends Analytic Framework 41
5.5 Choroidal Neovascularization Therapeutics Market – Clinical Pipeline by Mechanism of Action 43
5.6 Choroidal Neovascularization Therapeutics – Promising Drugs Under Clinical Development 43
5.7 Molecule Profile for Promising Drugs under Clinical Development 44
5.7.1 VEGF Trap-Eye 44
5.8 Key Takeaway 44
6 Choroidal Neovascularization Therapeutics - Clinical Trials Mapping 45
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Prominent Sponsors 48
6.5 Top Companies Participating in Choroidal Neovascularization Therapeutics Clinical Trials 50
7 Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Future Market Competition Scenario 52
7.3 Choroidal Neovascularization Therapeutics - Implications for Future Market Competition 53
8 Choroidal Neovascularization Therapeutics - Future Players 54
8.1 Introduction 54
8.2 Company Profiles 54
8.2.1 F. Hoffmann-La Roche 54
8.2.2 Bayer AG 58
8.2.3 Regeneron Pharmaceuticals, Inc. 61
8.3 Other Companies in CNV Therapeutics Market 62
9 Choroidal Neovascularization Therapeutics - Licensing and Partnership Deals 64
10 Choroidal Neovascularization Therapeutics - Appendix 66
10.1 Market Definitions 66
10.2 Abbreviations 66
10.3 Methodology 67
10.3.1 Coverage 67
10.3.2 Secondary Research 67
10.3.3 Forecasting 68
10.3.4 Primary Research 70
10.3.5 Expert Panel Validation 70
10.4 Contact Us 70
10.5 Disclaimer 70
10.6 Bibliography 71"

1.1 List of Tables
Table 1: Choroidal Neovascularization- Classification 6
Table 2: Choroidal Neovascularization Therapeutics Market, Global, Revenue ($m), 2005-2010 13
Table 3: Choroidal Neovascularization Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Table 4: Choroidal Neovascularization Therapeutics Market, the US, Revenue ($m), 2005–2010 15
Table 5: Choroidal Neovascularization Therapeutics Market, the US, Forecast ($m), 2010–2017 16
Table 6: Choroidal Neovascularization Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 7: Choroidal Neovascularization Therapeutics Market, France, Forecast ($m), 2010–2017 18
Table 8: Choroidal Neovascularization Therapeutics Market, Germany, Revenue ($m),  2005–2010 19
Table 9: Choroidal Neovascularization Therapeutics Market, Germany, Forecast ($m),  2010–2017 20
Table 10: Choroidal Neovascularization Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 11: Choroidal Neovascularization Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Table 12: Choroidal Neovascularization Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 13: Choroidal Neovascularization Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Table 14: Choroidal Neovascularization Therapeutics Market, the UK, Revenue ($m), 2005–2010 25
Table 15: Choroidal Neovascularization Therapeutics Market, the UK, Forecast ($m), 2010–2017 26
Table 16: Choroidal Neovascularization Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 17: Choroidal Neovascularization Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Table 18: Lucentis- Annual sales 2006-2010 33
Table 19: Visudyne Annual Sales ($m), 2006-2010 35
Table 20: Choroidal Neovascularization Therapeutics – Phase III Pipeline, 2011 39
Table 21: Choroidal Neovascularization Therapeutics – Phase II Pipeline, 2011 39
Table 22: Choroidal Neovascularization Therapeutics – Phase I Pipeline, 2011 40
Table 23: Choroidal Neovascularization Therapeutics- Discovery and Pre-clinical Pipeline, 2011 40
Table 24: CNV Therapeutics – Most Promising Drugs Under Clinical Development, 2011 43
Table 25: Choroidal Neovascularization Therapeutics – Clinical Trials by Country, 2011 45
Table 26: Choroidal Neovascularization Therapeutics – Clinical Trials by Phase, 2011 46
Table 27: Choroidal Neovascularization Therapeutics – Clinical Trials by Status, 2011 47
Table 28: Choroidal Neovascularization Therapeutics – Prominent Sponsors, 2011 49
Table 29: Choroidal Neovascularization Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Table 30: F. Hoffman-La Roche- Deals 2009-2010 56
Table 31: Bayer AG Deals, 2009-2010 59
Table 32: Choroidal Neovascularization Therapeutics Market – Future Players, 2011 62
Table 33: Choroidal Neovascularization Therapeutics, Global, Deals, 2009-2011 64"

1.2 List of Figures
Figure 1: Fluorescein Angiograms of Choroidal Neovascularization Types 6
Figure 2: Progression of CNV 7
Figure 3: When Focusing on the Center of an Amsler Grid (a), a Patient with CNV Perceives the Grid as Distorted (b) 9
Figure 4: Treatment Options for CNV 10
Figure 5: Choroidal Neovascularization Therapeutics Market, Global, Revenue ($m), 2005-2010 12
Figure 6: Choroidal Neovascularization Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Figure 7: Choroidal Neovascularization Therapeutics Market, the US, Revenue ($m), 2005–2010 15
Figure 8: Choroidal Neovascularization Therapeutics Market, the US, Forecast ($m),  2010–2017 16
Figure 9: Choroidal Neovascularization Therapeutics Market, France, Revenue ($m), 2005–2010 17
Figure 10: Choroidal Neovascularization Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 11: Choroidal Neovascularization Therapeutics Market, Germany, Revenue ($m),  2005–2010 19
Figure 12: Choroidal Neovascularization Therapeutics Market, Germany, Forecast ($m),  2010–2017 20
Figure 13: Choroidal Neovascularization Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 14: Choroidal Neovascularization Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 15: Choroidal Neovascularization Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 16: Choroidal Neovascularization Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 17: Choroidal Neovascularization Therapeutics Market, the UK, Revenue ($m), 2005–2010 25
Figure 18: Choroidal Neovascularization Therapeutics Market, the UK, Forecast ($m), 2010–2017 26
Figure 19: Choroidal Neovascularization Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 20: Choroidal Neovascularization Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 21: Opportunity and Unmet Need in the Choroidal Neovascularization Therapeutics Market 30
Figure 22: Strategic Competitor Assessment of the Major Marketed Products in CNV, 2010 32
Figure 23: Choroidal Neovascularization Therapeutics – Pipeline by Phase of Development, 2011 38
Figure 24: Choroidal Neovascularization Therapeutics – Technology Trends Analytics Framework, 2011 41
Figure 25: Choroidal Neovascularization Therapeutics – Technology Trends Analytics Framework – Description, 2011 42
Figure 26: Choroidal Neovascularization Therapeutics – Pipeline by Mechanism of Action, 2011 43
Figure 27: Choroidal Neovascularization Therapeutics – Clinical Trials by Country, 2011 45
Figure 28: Choroidal Neovascularization Therapeutics – Clinical Trials by Phase, 2011 46
Figure 29: Choroidal Neovascularization Therapeutics – Clinical Trials by Status, 2011 47
Figure 30: Choroidal Neovascularization Therapeutics – Overall Sponsors, 2011 48
Figure 31: Choroidal Neovascularization Therapeutics – Prominent Sponsors, 2011 48
Figure 32: Choroidal Neovascularization Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Figure 33: Key Events Competition in the CNV Therapeutics Market, 2011 51
Figure 34: Implications for Future Market Competition in the Choroidal Neovascularization Market, 2011 53
Figure 35: Choroidal Neovascularization Therapeutics Market – Pipeline by Company, 2011 54
Figure 36: GlobalData Market Forecasting Model 69